Paris Hilton Shares Her Experience with JORNAY PM and Launches New ‘Embrace Your Sparkle’ Campaign with Collegium to Empower the ADHD Community




Paris Hilton Shares Her Experience with JORNAY PM and Launches New ‘Embrace Your Sparkle’ Campaign with Collegium to Empower the ADHD Community

– Paris Hilton shares her personal ADHD journey and encourages others to see ADHD in a new light –

–Together, Paris and Collegium are reframing common stereotypes and highlighting experiences that are often part of living with ADHD, including the importance of talking to a doctor and finding an individualized treatment plan –

         
Credit: Ashley Osborn

STOUGHTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company, and Paris Hilton, an entrepreneur, musician, author, and advocate, announced today ‘Embrace Your Sparkle’, a campaign aimed at encouraging broader understanding and open dialogue about attention-deficit/hyperactivity disorder (ADHD).

ADHD affects approximately 15.5 million adults¹ and 6.5 million children in the U.S.² with an estimated 70% continuing to experience symptoms into adulthood³. However, ADHD remains frequently underrecognized in adults, contributing to delayed diagnosis^4,5. And for many, the diagnosis comes with a stigma, often in the forms of stereotypes, prejudice, and discrimination⁶.

For Paris, living with ADHD has included moments shaped by stigma and self-doubt, but it has also brought a creative spark, inspired innovation in her business endeavors, and shaped a unique way of approaching the world. Through ‘Embrace Your Sparkle’, she is sharing her story to help broaden the narrative around ADHD and normalize conversations not only about the diagnosis itself, but about how people manage it in their everyday lives.

“I’ve learned to look at ADHD from a different perspective,” said Paris Hilton. “‘Embrace Your Sparkle’ reminds me that ADHD can be a source of creativity and courage. At the same time, the day-to-day challenges of ADHD symptoms are very real. There are days when balancing motherhood, music, and work feels overwhelming, and I know so many people can relate to that.”

“ADHD shows up differently for everyone, and too often those experiences are disregarded or minimized,” said Scott Dreyer, Executive Vice President, Chief Commercial Officer of Collegium Pharmaceutical. “Paris brings an authentic and powerful perspective to help shine a light on the everyday realities of living with ADHD and the importance of finding support that fits each individual.”

Paris’ Treatment Experience to Help Manage ADHD Symptoms

It may not have been apparent to others, but staying focused was a daily struggle for Paris. Her ADHD symptoms often felt most difficult at the start of the day – when mornings became overwhelming, and it felt like she was behind before the day even began. After speaking with her doctor, she found a treatment plan to help manage her symptoms and support her routine and needs.

For Paris, that plan includes JORNAY PM® (methylphenidate HCl) extended-release capsules, CII, a central nervous system (CNS) stimulant indicated for the treatment of ADHD in patients 6 years and older. JORNAY PM is taken in the evening and is designed to begin working in the morning with lasting symptom support throughout the day and into the early evening. JORNAY PM may help increase attention and decrease impulsiveness and hyperactivity.

Paris explained, “I like that I take JORNAY PM at night, because it fits into my routine. When I wake up, it’s already working and lasts throughout my day into early evening.”

Paris’ experience reflects her individual treatment journey. Individual results may vary. Individuals should consult a healthcare provider to discuss appropriate ADHD treatment options.

What is JORNAY PM?

JORNAY PM is a central nervous system (CNS) stimulant prescription medicine used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in people 6 years of age and older. JORNAY PM may help increase attention and decrease impulsiveness and hyperactivity in people 6 years of age and older with ADHD. JORNAY PM is not recommended for use in children under 6 years of age with ADHD.

IMPORTANT SAFETY INFORMATION

JORNAY PM is a federally controlled substance (CII) because it contains methylphenidate and has a high chance of abuse and misuse and may lead to substance use problems, including addiction. Misuse and abuse of JORNAY PM can lead to overdose and death, which is increased with higher doses of JORNAY PM or if it is used in ways that are not approved, such as snorting or injection. Your healthcare provider (HCP) should check for signs of abuse, misuse, and addiction before starting and during treatment with JORNAY PM. JORNAY PM may lead to physical dependence after prolonged use, even if taken as directed by your HCP. Tell your HCP if you or your child have ever abused or been dependent on alcohol, prescription medicines, or street drugs.

JORNAY PM can be a target for people who abuse prescription medicines or street drugs. Keep JORNAY PM in a safe place to protect it from theft. Never give your JORNAY PM to anyone else, because it may cause death or harm them. Selling or giving away JORNAY PM may harm others and is against the law.

JORNAY PM should not be taken if you or your child is allergic to methylphenidate or any of the ingredients in JORNAY PM or is taking or has taken an antidepressant called a monoamine oxidase inhibitor (MAOI) within the last 14 days.

JORNAY PM may cause other serious side effects, including:

• Risks for people with serious heart disease. Sudden death has happened in people who have heart defects or other serious heart disease. Your HCP should check carefully for heart problems before starting JORNAY PM. Tell your HCP about any heart problems, heart disease, or heart defects. Call your HCP or go to the nearest hospital emergency room right away if there are any signs of heart problems, such as chest pain, shortness of breath, or fainting during treatment.
• Increased blood pressure and heart rate. Blood pressure and heart rate should be checked regularly during treatment.
• Mental (psychiatric) problems, including new or worse behavior and thought problems, new or worse bipolar illness, new psychotic symptoms (such as hearing voices or seeing or believing things that are not real) or new manic symptoms. Tell your HCP about any mental problems, or about a family history of suicide, bipolar illness, or depression. Call your HCP right away if there are any new or worsening mental symptoms or problems during treatment.
• Painful and prolonged erections (priapism) in males. If painful and prolonged erections happen, get medical help right away.
• Circulation problems in fingers and toes (peripheral vasculopathy, including Raynaud’s phenomenon). Signs and symptoms may include fingers or toes feeling numb, cool, painful, sensitive to temperature, and/or changing color from pale, to blue, to red. Tell your HCP about any circulation problems in fingers or toes. Call your HCP right away if any signs of unexplained wounds appear on fingers or toes.
• Slowing of growth (height and weight) in children. Children should have their height and weight checked often while taking JORNAY PM.
• Eye problems (increased pressure in the eye and glaucoma). Tell your HCP about any eye problems. Call your HCP right away if changes in vision or eye pain, swelling, or redness occurs.
• New or worsening tics or worsening Tourette’s syndrome. Tell your HCP if any new or worsening tics or worsening Tourette’s syndrome occurs.

Before taking JORNAY PM, tell your HCP if you or your child:

• are pregnant or plan to become pregnant. It is not known if JORNAY PM will harm an unborn baby.
• are breastfeeding or plan to breastfeed. JORNAY PM passes into the breast milk.

Tell your HCP about all of the medicines that you or your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements. JORNAY PM and some medicines may interact with each other and cause serious side effects. Especially tell your HCP if you or your child takes medicine to treat depression, including MAOIs.

Avoid drinking alcohol during treatment with JORNAY PM. This may cause a faster release of the medicine in JORNAY PM.

The most common side effects of methylphenidate include decreased appetite, trouble sleeping, nausea, vomiting, indigestion, stomach pain, weight loss, anxiety, dizziness, irritability, mood swings (affect lability), increased heart rate, and increased blood pressure.

The most common side effects of JORNAY PM in clinical studies in children ages 6 to 12 with ADHD include trouble sleeping, decreased appetite, restlessness (psychomotor hyperactivity), headache, nausea, mood swings and vomiting. These are not all the possible side effects of JORNAY PM.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.  

Please see Medication Guide, and full Prescribing Information, including Boxed Warning.  

Learn more at JORNAYPM.com or follow JORNAY PM on Instagram and Facebook.  

For more information about ‘Embrace Your Sparkle’, visit jornaypm.com/embrace-your-sparkle.

About​ ​Collegium Pharmaceutical, Inc.  
Collegium is a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business driven by JORNAY PM. Collegium’s strategy includes growing its commercial portfolio and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts.   

For more information about Collegium, please visit www.collegiumpharma.com and follow on LinkedIn and @CollegiumPharma on X.    

References 

1. Centers for Disease Control and Prevention. Attention-Deficit/Hyperactivity Disorder Diagnosis, Treatment, and Telehealth Use in Adults — National Center for Health Statistics Rapid Surveys System, United States, October–November 2023. Accessed October 1, 2025. https://www.cdc.gov/mmwr/volumes/73/wr/pdfs/mm7340a1-H.pdf
2. Danielson, M. L. et al. (2024) ‘ADHD Prevalence Among U.S. Children and Adolescents in 2022: Diagnosis, Severity, Co-Occurring Disorders, and Treatment’, Journal of Clinical Child & Adolescent Psychology, 53(3), pp. 343–360. doi: 10.1080/15374416.2024.2335625.
3. Cortese, S., Bellgrove, M. A., Brikell, I., Franke, B., Goodman, D. W., Hartman, C. A., Larsson, H., Levin, F. R., Ostinelli, E. G., Parlatini, V., Ramos-Quiroga, J. A., Sibley, M. H., Tomlinson, A., Wilens, T. E., Wong, I. C. K., Hovén, N., Didier, J., Correll, C. U., Rohde, L. A., & Faraone, S. V. (2025). Attention-deficit/hyperactivity disorder (ADHD) in adults: evidence base, uncertainties and controversies. World psychiatry: official journal of the World Psychiatric Association (WPA), 24(3), 347–371. https://doi.org/10.1002/wps.21374
4. Johnson, J., Morris, S., & George, S. (2020). Misdiagnosis and missed diagnosis of adult attention-deficit hyperactivity disorder, BJPsych Advances, Volume 27, Issue 1, January 2021, pp. 60 – 61. DOI: https://doi.org/10.1192/bja.2020.34
5. Rivas-Vazquez, R.A., Diaz, S.G., Visser, M.M., Rivas-Vazquez, A.A. (2023). Adult ADHD: Underdiagnosis of a Treatable Condition. J Health Serv Psychol, 49(1):11-19. doi: 10.1007/s42843-023-00077-w. Epub 2023 Jan 28. doi:10.1007/s42843-023-00077-w
6. Visser, M. J., Peters, R. M. H., & Lumen M. (2024). Understanding ADHD-related stigma: A gender analysis of young adult and key stakeholder perspectives, Neurodiversity, 2, pp. 1-14. DOI: 10.1177/27546330241274664.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “forecasts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements related to the objectives and potential impact of the ‘Embrace Your Sparkle’ campaign and other statements that are not historical facts. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the company’s current expectations, including risks relating to, among others: unknown liabilities; risks related to future opportunities and plans for our products, including uncertainty of the expected financial performance of such products; our ability to commercialize and grow sales of our products; our ability to manage our relationships with licensors; the success of competing products that are or become available; our ability to maintain regulatory approval of our products, and any related restrictions, limitations, and/or warnings in the label of our products; the size of the markets for our products, and our ability to service those markets; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products; the costs of commercialization activities, including marketing, sales and distribution; changing market conditions for our products; the outcome of any patent infringement or other litigation that may be brought by or against us; the outcome of any governmental investigation related to our business; our ability to secure adequate supplies of active pharmaceutical ingredient for each of our products and manufacture adequate supplies of commercially saleable inventory; our ability to obtain funding for our operations and business development; regulatory developments in the U.S.; our expectations regarding our ability to obtain and maintain sufficient intellectual property protection for our products; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency compliance; our customer concentration; and the accuracy of our estimates regarding expenses, revenues, capital requirements and need for additional financing. These and other risks are described under the heading “Risk Factors” in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Media Contact: 
Jessica Cotrone
Senior Vice President, Communications & Corporate Affairs
communications@collegiumpharma.com

Investor Contacts:
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com

Danielle Jesse
Director, Investor Relations
ir@collegiumpharma.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/cefb4315-8163-4975-8a6d-478e0ef982de

PP-JNY-US-0668 03/26 

Nanox Signs Distribution Agreement with Imperial Imaging Technology to Expand Nanox.ARC Access Across U.S. Southeast




Nanox Signs Distribution Agreement with Imperial Imaging Technology to Expand Nanox.ARC Access Across U.S. Southeast

Agreement with Imperial Imaging strengthens Nanox’s commercial rollout across the orthopedic-rich segment in six U.S. Southeast states.

Distribution Agreement Supports U.S. Market Expansion

PETACH TIKVA, Israel, March 03, 2026 (GLOBE NEWSWIRE) — Nano-X Imaging Ltd. (NASDAQ: NNOX), a leader in innovative medical imaging technology, today announced that its US-based subsidiary, Nanox Impact Inc. has signed a new distribution agreement with Imperial Imaging Technology LLC, a Georgia based provider of diagnostic imaging solutions.

The collaboration will support the commercial rollout of the Nanox.ARC, a multisource digital tomosynthesis system that makes 3D imaging possible in more clinical settings, at a lower cost and reduced radiation dose compared to traditional CT, across key regional markets in the United States.

Under the terms of the agreement, Imperial Imaging Technology will serve as a distributor for the Nanox.ARC system and related services across Georgia, Alabama, Tennessee, North Carolina, South Carolina, and Northern Florida. Imperial will lead its marketing and sales efforts and provide ongoing customer support. Imperial will coordinate product demonstrations and facilitate clinical evaluations for orthopedic practices and healthcare facilities in the territory in connection with opportunities pursued by Imperial.

Nanox is advancing its channel partner strategy in the United States, building a geographically diverse network of regional distributors with deep domain expertise. This distribution agreement expands Nanox’s footprint across the Southeast, a significant growing market for orthopedic services, aligning the company with a partner that owns deep experience supporting orthopedic and musculoskeletal practices (MSK), including familiarity with clinical workflows and point-of-care imaging cases.

Together, Nanox and Imperial Imaging aim to expand access to advanced MSK imaging directly within orthopedic practices. Keeping imaging closer to the point of care reduces the need for patients to travel to off-site imaging centers or emergency departments, improves continuity of care, and enables more efficient clinical workflows. Since Nanox.ARC’s DTS imaging is reimbursable under an existing CPT code and no pre-authorization is required, it can help reduce administrative burden and speed up patient treatment while improving affordability for clinics.

Founded in 2019 and headquartered in Marietta, Georgia, Imperial Imaging has rapidly grown into a leading independent distributor serving hospitals, orthopedic practices, urgent care centers, surgery centers, and other clinical facilities. Imperial Imaging brings deep relationships within the orthopedic community across its six-state territory and known for its high-quality service and installation expertise. Its portfolio covers X-ray, MRI, ultrasound, CT, and comprehensive service programs tailored to clinical workflows. The company was recently named to the Inc. 5000 list, underscoring its strong market momentum.

“We are pleased to welcome Imperial Imaging into our growing network of U.S. distribution partners,” said Erez Meltzer, CEO and Acting Chairman of the Board of Nanox. “This collaboration reflects our commitment to regional strategies that pair advanced imaging technology with trusted, relationship-driven distribution. Imperial Imaging’s strong presence, especially in the orthopedic community, makes them an ideal partner for bringing the Nanox.ARC to more practices and patients across the Southeast.”

“We chose to partner with Nanox for the deployment of multiple systems as the Nanox.ARC aims to support clinicians in revealing new or undetected clinical findings bringing value in orthopedic point of care imaging. Keeping imaging closer to the point of care reduces the need for patients to travel to off-site imaging centers or emergency departments, improves continuity of care, and enables more efficient clinical workflows. The system is reimbursable under an existing CPT code and no pre-authorization is required, which can reduce administrative burden and speed up patient treatment while improving affordability for clinics,” Aaron Pressley, President of Imperial Imaging Technology. We’re excited to bring this advanced technology to the orthopedic community across the Southeast.”

About Nanox

Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform.

Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care.

Nanox’s vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes.

The Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT, which combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.

By integrating imaging technology, AI, cloud infrastructure, clinical expertise, a marketplace, and health information technology, Nanox seeks to lower barriers to adoption, improve utilization, and advance preventive care worldwide. For more information, please visit www.nanox.vision

Forward-Looking Statements

This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (iv) Nanox’s ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (v) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vi) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (vii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; (viii) Nanox’s ability to conduct business globally; (ix) changes in global, political, economic, business, competitive, market and regulatory forces; (x) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xi) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things; and (xii) potential litigation associated with our transactions.

For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations.

Contacts

Media Contact:
Ben Shannon
ICR Healthcare
NanoxPR@icrinc.com

Investor Contact:
Mike Cavanaugh
ICR Healthcare
mike.cavanaugh@icrhealthcare.com

Inspire Medical Systems, Inc. to Present at the KeyBanc Capital Markets Healthcare Forum




Inspire Medical Systems, Inc. to Present at the KeyBanc Capital Markets Healthcare Forum

MINNEAPOLIS, March 03, 2026 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the KeyBanc Capital Markets Healthcare Forum on Tuesday, March 17, 2026.

Inspire is scheduled to present at 1:30 p.m. Eastern Time. The presentation will be accessible via a live webcast here.

A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire’s Investor website at https://investors.inspiresleep.com.

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443

Prolium Bioscience Launches with $50 Million and Announces First Patients Dosed with PRO-203, a Potential Best-in-Class CD20xCD3 T-Cell Engager, for Severe Autoimmune Disease




Prolium Bioscience Launches with $50 Million and Announces First Patients Dosed with PRO-203, a Potential Best-in-Class CD20xCD3 T-Cell Engager, for Severe Autoimmune Disease

Initial $50M Series A investment from founding investor RTW Investments

Proceeds will fund clinical development of PRO-203 in systemic sclerosis (SSc) and multiple additional severe autoimmune diseases

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) — Prolium Bioscience, Inc. (Prolium), a clinical stage biotechnology company, today announced its launch with a $50 million Series A Financing to develop PRO-203, a potential best-in-class CD20xCD3 T-cell engager, for severe autoimmune disease. The financing was led by its founding investor, RTW Investments (RTW).

Prolium announced that it has begun dosing healthy volunteers in an ongoing single ascending dose study of PRO-203 and expects to initiate a multinational Phase 1/2 study of PRO-203 in systemic sclerosis (SSc) in Q2 2026. Additionally, five patients with treatment-refractory, advanced systemic lupus erythematosus (SLE), all of whom also have lupus nephritis (LN), have been treated with PRO-203 in an investigator-initiated study. Results will be reported at a future medical conference. Prolium plans to initiate further clinical studies this year in additional severe autoimmune diseases that are driven predominantly by aberrant B-cells. 

“T-cell engagers are the next frontier in treating autoimmune disease, with the potential to achieve deep B-cell depletion in tissues, like CAR-T, without many of the challenges of CAR-T,” said Scott Requadt, CEO of Prolium. “CD20 is the most well-validated target in B-cell driven autoimmune diseases. Based on promising initial safety and efficacy data, we are excited about the potential of PRO-203 to achieve deep, durable remissions in patients with autoimmune disease and to be an important new therapy for scleroderma and other serious autoimmune diseases.”

“PRO-203 has the potential to change the treatment paradigm in scleroderma and other serious autoimmune diseases,” said Peter Fong, Partner and President, RTW. “Prolium’s team is executing impressively to generate substantial data readouts of PRO-203 in several autoimmune disorders within the next two years.”

Prolium was founded in 2025 by RTW, which invested $50 million in the company. PRO-203 works by binding both CD20+ B-cells and CD3 on T-cells, forming an immunological synapse around the target cells and recruiting effector T cells to the vicinity of target cells, thereby redirecting T-cells to eradicate B-cells via T-cell dependent cellular cytotoxicity (TDCC). The company in-licensed global rights in all non-oncology indications and ex-Asia rights for oncology indications to PRO-203 from KeyMed Biosciences and InnoCare Pharma. PRO-203 has previously been studied in a Phase 1/2 trial in relapsed/refractory Non-Hodgkin Lymphoma (NHL) patients in China, resulting in an overall complete response (CR) rate of 59% and an overall response rate (ORR) of 82% in patients dosed at therapeutic levels.

About Prolium

Prolium Bioscience is a clinical stage company developing PRO-203, a potential best-in-class, bispecific CD20xCD3 antibody for systemic sclerosis and other severe autoimmune diseases. Founded and backed by RTW Investments, Prolium has assembled a team with deep experience in the development of therapeutics in autoimmune disease. For more information about Prolium, please visit www.proliumbio.com.

About RTW Investments, LP

RTW Investments, LP is a New York-based, global, full life-cycle investment firm that focuses on identifying transformational and disruptive innovations across the biopharmaceutical and medical technologies sectors. As a leading partner of industry and academia, RTW combines deep scientific expertise with a solution-oriented investment approach to advance emerging therapies by building and supporting the companies developing them. For further information about RTW, please visit www.rtwfunds.com

Investor & Media Contact:
Chris Brinzey
ICR Healthcare
Chris.Brinzey@icrhealthcare.com